142 related articles for article (PubMed ID: 9710113)
1. Meropenem monotherapy as empiric treatment of nosocomial lower respiratory tract infection.
Sieger B
Crit Care Med; 1998 Aug; 26(8):1462-3. PubMed ID: 9710113
[No Abstract] [Full Text] [Related]
2. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group.
Sieger B; Berman SJ; Geckler RW; Farkas SA
Crit Care Med; 1997 Oct; 25(10):1663-70. PubMed ID: 9377880
[TBL] [Abstract][Full Text] [Related]
3. [Comparative activity of meropenem and other antibiotics against the pathogens of nosocomial infections].
Sidorenko SV; Rezvan SP; Grudinina SA; Sterkhova GV; Aleksandrova IA
Antibiot Khimioter; 1998; 43(1):4-14. PubMed ID: 9532326
[TBL] [Abstract][Full Text] [Related]
4. The role of carbapenems in the treatment of severe nosocomial respiratory tract infections.
Joseph J; Rodvold KA
Expert Opin Pharmacother; 2008 Mar; 9(4):561-75. PubMed ID: 18312158
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of monotherapy by meropenem in ventilator-associated pneumonia].
Alvarez Lerma F;
Antibiot Khimioter; 2001; 46(12):42-52. PubMed ID: 12108093
[TBL] [Abstract][Full Text] [Related]
6. Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.
Finch RG; Pemberton K; Gildon KM
J Chemother; 1998 Feb; 10(1):35-46. PubMed ID: 9531074
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
8. [Multicentre study of comparative efficacy of meropenem and combined regimens for empirical antibacterial therapy of severe nosocomial infections: results of clinical and pharmacoeconomic analysis].
Iakovlev SV; Beloborodov VB; Sidorenko SV; Iakovlev VP; Grigor'ev KB; Eliseeva EV; Kon EM; Levit AL; Kostina GV; Kuprenkov AV; Mukhacheva SIu; Saturnov AV; Sergeev IN; Spasov GP; Stakanov AV; Ushakova MA
Antibiot Khimioter; 2006; 51(7):15-27. PubMed ID: 18035730
[TBL] [Abstract][Full Text] [Related]
9. Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group.
Mouton YJ; Beuscart C
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():145-56. PubMed ID: 8543490
[TBL] [Abstract][Full Text] [Related]
10. [Comparative pharmacoeconomic evaluation of various approaches to antibacterial therapy of ventilator-associated pneumonia].
Rudnov VA
Antibiot Khimioter; 2001; 46(12):22-6. PubMed ID: 12108089
[No Abstract] [Full Text] [Related]
11. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia.
Alvarez Lerma F;
J Chemother; 2001 Feb; 13(1):70-81. PubMed ID: 11233804
[TBL] [Abstract][Full Text] [Related]
12. [Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections].
Iakovlev SV; Iakovlev VP; Derevianko II; Kira EF;
Antibiot Khimioter; 1998; 43(1):15-23. PubMed ID: 9532327
[TBL] [Abstract][Full Text] [Related]
13. Empiric monotherapy for febrile neutropenia--a randomized study comparing meropenem with ceftazidime.
Lindblad R; Rödjer S; Adriansson M; Andreasson B; Bäckström B; Johansson P; Karlsson K; Rhedin C; Turesson I
Scand J Infect Dis; 1998; 30(3):237-43. PubMed ID: 9790130
[TBL] [Abstract][Full Text] [Related]
14. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Louie A; Liu W; Fikes S; Brown D; Drusano GL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
[TBL] [Abstract][Full Text] [Related]
15. Hydrolysis of imipenem, meropenem, ceftazidime, and cefepime by multiresistant nosocomial strains of Sphingobacterium multivorum.
Blahová J; Králiková K; Krcméry V; Kubonová K
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):178-80. PubMed ID: 9105852
[No Abstract] [Full Text] [Related]
16. Cefepime versus ceftazidime: considerations for empirical use in critically ill patients.
Roberts JA; Webb SA; Lipman J
Int J Antimicrob Agents; 2007 Feb; 29(2):117-28. PubMed ID: 17158033
[TBL] [Abstract][Full Text] [Related]
17. Empiric Meropenem-based versus Ceftazidime-based Therapy for Severe Community-Acquired Pneumonia in a Retrospective Cohort Study.
Chua NG; Liew YX; Lee W; Tang SS; Zhou YP; Patel K; Kwa AL; Chlebicki MP
Ann Acad Med Singap; 2019 Mar; 48(3):98-103. PubMed ID: 30997479
[No Abstract] [Full Text] [Related]
18. Nosocomial pneumonia. Diagnostic and therapeutic considerations.
Cunha BA
Med Clin North Am; 2001 Jan; 85(1):79-114. PubMed ID: 11190353
[TBL] [Abstract][Full Text] [Related]
19. Meropenem versus ceftazidime as empirical monotherapy for febrile neutropenic cancer patients.
Vandercam B; Gérain J; Humblet Y; Ferrant A; Wauters G; Moreau M; Longueville J; Symann M; Straetmans N
Ann Hematol; 2000 Mar; 79(3):152-7. PubMed ID: 10803938
[TBL] [Abstract][Full Text] [Related]
20. Meropenem compared with ceftazidime in the empiric treatment of acute severe infections in hospitalized children. Italian Pediatric Meropenem Study Group.
Principi N; Marchisio P
J Chemother; 1998 Apr; 10(2):108-13. PubMed ID: 9603635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
